Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders
April 30, 2021 02:00 ET
|
BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at...
Biophytis Receives €980,000 DeepTech Funding from BPI France for the development of Macuneos (BIO201) in Dry AMD
April 29, 2021 02:00 ET
|
BIOPHYTIS SA
DeepTech funding supports advanced and highly differentiating biotech projects with significant commercial potentialBiophytis plans to initiate Phase 1 clinical trial in the second half of 2021 PARIS...
Biophytis - Convening of Another Combined General Meeting at a Later Date
April 27, 2021 02:00 ET
|
BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at...
Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on April 26, 2021
April 26, 2021 02:00 ET
|
BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that are...
BIOPHYTIS Identifies False Report Regarding COVA study
April 13, 2021 17:00 ET
|
BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of...
BIOPHYTIS Gives Updates on its Phase 2-3 COVA Study on COVID-19
March 22, 2021 03:00 ET
|
BIOPHYTIS SA
The Company receives a favorable opinion from the DMC on the safety of Sarconeos (BIO101) in the COVA study following first interim analysisPatient enrollment has now reached 97 of the 155 planned for...
Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis Against Negma Group Ltd
March 19, 2021 18:00 ET
|
BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., March 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company...
Biophytis’ Combined Annual General Meeting Will Take Place on April 26, 2021 behind closed doors
March 10, 2021 22:08 ET
|
BIOPHYTIS SA
Legally required documents for shareholders’ votes are available on Biophytis website PARIS and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth...
Biophytis Reports 2020 Full Year Results
February 26, 2021 02:00 ET
|
BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company...
Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities Approvals in France and Belgium
February 17, 2021 02:00 ET
|
BIOPHYTIS SA
Clinical centers in France and Belgium will begin recruitment for Part 2 of the COVA Study following authorization from Regulatory AuthoritiesThese approvals follow the previous authorizations...